Tag Archives: Specialty Pharmaceuticals

Jim Greenwood in New York Times: Specialty Tiers Limit Patient Access

Jim Greenwood

Today, the New York Times published a letter from Jim Greenwood, BIO’s President and CEO. Greenwood’s letter discusses the problems that expanded use of specialty tier cost-sharing by the insurance industry are posing for patients, limiting their access to lifesaving therapies and cures. Breakthrough treatments cost billions of dollars, and investors will only take on such risks if they can expect a reasonable return on their investment. The full text of the letter is below: To Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Beggar-Thy-Neighbor Medicine: Wall Street Journal Op-Ed


In an editorial about specialty drug prices, the Wall Street Journal writes: “To understand how ObamaCare is already bending the future of U.S. medical progress, consult the furor over specialty drug prices, as an alliance of convenience among third-party payers assails pharmaceutical innovation as too costly. Maybe patients should give up on cures and, as President Obama once put it, just take the painkiller…” Read the full opinion

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

The Rise of Specialty Pharmaceuticals

Albert Thigpen

Fact: Specialty pharmaceuticals represented nearly 25 percent of all drug spending last year. By 2018, it’s estimated they’ll account for nearly half of the 100 top-selling medications on the market. With an average cost for a specialty medical therapy hovering around $35,000 to $75,000 per patient per year, this is an area that is getting the attention of top industry players – from biopharma who see the market opportunity to healthcare payors like health plans Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,